Skip to main content
. 2019 Aug 22;9(2):195–218. doi: 10.1016/j.jcmgh.2019.08.004

Figure 13.

Figure 13

Effect of nivolumab therapy on HCC patients. (A, E, and I) tSNE maps of CD8+ TILs from patients before nivolumab treatment. (A and E) Responder and (I) nonresponder patients. (B, F, and J) tSNE maps of CD8+ TILs from patients on nivolumab therapy. (B and F) Responder and (J) nonresponder patients. (C, G, and M) tSNE maps indicating individual clusters of CD8+ TILs in (C and G) responder and (K) nonresponder patients. (D, H, and L) Heatmaps of the normalized expression of each marker for indicated clusters. The purple asterisks indicate TIL clusters enriched in pretreatment samples and the yellow asterisks indicate TIL clusters enriched in on-therapy samples. Color scales indicate the relative expression levels of the indicated marker.